- 351studies in the library match, of 29,380
- 98name it in the title
- 2011–2026years published
- 329peer-reviewed articles
The query: title or abstract mentions "ARIA", "ARIA-E", "ARIA-H" or "amyloid-related imaging abnormalities", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,380 study records, as of 2026-11-08. Every count on this page comes from that match. The matched list as JSON.
Amyloid-related imaging abnormalities are changes seen on MRI in some people treated with anti-amyloid antibodies: ARIA-E is fluid build-up or swelling, ARIA-H is small bleeds or iron deposits. Many cases cause no symptoms and are found only on scheduled scans; some cause headache, confusion or other symptoms, and a few have been serious.
The rate depends on the drug, the dose and especially on APOE ε4 status: people with two copies of ε4 have the highest rates in every trial. Those relationships are what the quoted papers measure.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 351 matched records are quoted; each links to its study page and from there to the paper.
“Amyloid-related imaging abnormalities-hemorrhage (ARIA-H) were similar (12.5% ABvac40; 15.0% placebo), with no ARIA-edema (ARIA-E) or meningoencephalomyelitis.”
“Amyloid-related imaging abnormality (ARIA)-edema/effusion occurred in 23.9% and 34.8% of donanemab- and aducanumab-treated participants, respectively.”
“The risk of amyloid-related imaging abnormalities (ARIA) was significantly higher in patients taking mAbs, including ARIA-edema (RR 7.7; 95% CI 4.60 to 13.00; p < 0.01), ARIA-hemorrhage (RR 1.8; 95% CI 1.22 to 2.59; p < 0.01), and symptomatic or serious ARIA (RR 14.1; 95% CI 7.30 to 27.14; p < 0.01).”
“They also increased risk for ARIA {RR = 4.30 [95 % CI (2.39; 7.77), I 2 = 86 %]} by a large effect size.”
“Gantenerumab was strongly associated with the occurrence of ARIA-E and ARIA-H: (19.67% vs.”
“Amyloid-related imaging abnormalities edema was observed in 19.2% (3 out of 11 were mildly symptomatic) of the gantenerumab group, 2.5% of the placebo group and 0% of the solanezumab group.”
“The safety of Donanemab was established with key adverse events related to Amyloid-Related Imaging Abnormalities (ARIA), ranging between 26.1 and 30.5% across the trials.”
“Amyloid-related imaging abnormalities-edema (ARIA-E) were the most common adverse event (AE); 61% of participants with ARIA-E were asymptomatic.”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 30 |
| Randomised controlled trial | 4 |
| Other clinical trial | 54 |
| Cohort or longitudinal study | 28 |
| Case-control study | 3 |
| Cross-sectional study | 5 |
| Other recorded design | 13 |
| No design recorded | 214 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 61 | |
| 2025 | 100 | |
| 2024 | 54 | |
| 2023 | 43 | |
| 2022 | 27 | |
| 2021 | 9 | |
| 2020 | 3 | |
| 2019 | 2 | |
| 2018 | 10 | |
| 2017 | 8 | |
| 2016 and earlier | 34 |
Other counts within the matched set
| Peer-reviewed articles | 329 |
| Marked open access in the record | 171 |
| Rated "high" evidence strength in alzhub's summary | 86 |
| Rated "moderate" evidence strength in alzhub's summary | 49 |
| Rated "low" evidence strength in alzhub's summary | 208 |
| No evidence-strength rating | 8 |
| Records stating a participant count | 116 |
| Median participants (those records) | 263 |
| Largest participant count | 1,307,937 |
Within the 351 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that also mention APOE ε4 | 104 | the abstract also contains "APOE", "ε4" or "e4" |
| …that also mention lecanemab | 146 | the abstract also contains "lecanemab" or "Leqembi" |
| …that also mention donanemab | 83 | the abstract also contains "donanemab" or "Kisunla" |
| …that also mention death or a fatal case | 28 | the abstract also contains "death", "fatal" or "died" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials
- Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
- Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients
- Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
- Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
- Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review
- Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data
- Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis
- Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study
- Amyloid-Related Imaging Abnormalities (ARIA) in Anti-Amyloid Therapies for Alzheimer's Disease: An Update from the Alzheimer's Association ARIA Workgroup
Systematic reviews and meta-analyses in the set
30 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Gantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta-Analysis
- Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease
- Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
- Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis
- Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials
Newest matched studies
- Serpin A3 is Increased in Cerebral Amyloid Angiopathy and ARIA
- Mapping post-translational modifications across amyloid-β deposits in Alzheimer’s disease: A neuropathologic survey with in vitro functional analysis of nitration
- Evaluation of plasma neurofilament and glial fibrillary acidic protein to predict or detect amyloid related imaging abnormalities
- Artificial Intelligence–Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration
- Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Journal of Alzheimer's disease : JAD | 21 |
| Alzheimer's research & therapy | 18 |
| The journal of prevention of Alzheimer's disease | 18 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 17 |
| Neurology | 17 |
Questions
- What is ARIA?
- Amyloid-related imaging abnormalities: MRI changes seen in some people on anti-amyloid antibodies, either swelling (ARIA-E) or small bleeds and iron deposits (ARIA-H). They are monitored with scheduled scans during treatment.
- Who is most at risk of ARIA?
- In every trial reported so far, people carrying two copies of the APOE ε4 variant had the highest rates, and rates also rose with dose. The papers below report the figures.
- How many studies on aria: brain swelling and bleeds does alzhub hold?
- 351 of the 29,380 study records in alzhub's library match the query "title or abstract mentions "ARIA", "ARIA-E", "ARIA-H" or "amyloid-related imaging abnormalities""; 98 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 30 systematic review or meta-analysis, 4 randomised controlled trials, 54 other clinical trials, 28 cohort or longitudinal studys, 3 case-control studys, 5 cross-sectional studys; 214 record no design.
- What is the most recent study in the set?
- "Serpin A3 is Increased in Cerebral Amyloid Angiopathy and ARIA" (bioRxiv, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Journal of Alzheimer's disease : JAD (21); Alzheimer's research & therapy (18); The journal of prevention of Alzheimer's disease (18), counted across the matched records.
Read on
- Anti-amyloid antibodies: what the trials showedThe ARIA rates from each FDA label.
- Lecanemab (Leqembi)One of the two approved antibodies.
- Donanemab (Kisunla)The other approved antibody.
- APOE4 and Alzheimer's riskThe gene variant that raises ARIA risk.